Vertaling van "new information or future " (Nederlands → Frans) :

DISCLOSURE NOTICE: The information contained in this release is as of September 1, 2010. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.
This release contains forward-looking information about an agreement by Pfizer to acquire FoldRx, and about FoldRx’s product candidate tafamidis, its other clinical and preclinical development programs and its technology platform, including their potential benefits, that involves substantial risks and uncertainties.

DISCLOSURE NOTICE: The information contained in this release is as of December 13, 2010. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.
This release contains forward-looking information that involves substantial risks and uncertainties concerning the possibility of future dividend increases.

The implementation of the new organisation chart as envisaged for the start of 2009 requires the P&O Service to develop a definition of its future role in terms of the expectations from the 3 Directorates-General and other departments and services, to implement the 1 % reduction imposed for personnel expenditure and to further develop the strategic decision to convert the FAMHP into a “learning organisation”.
The implementation of the new organisation chart as envisaged for the start of 2009 requires the P&O Service to develop a definition of its future role in terms of the expectations from the 3 Directorates-General and other departments and services, to implement the 1 % reduction imposed for personnel expenditure and to further develop the strategic decision to convert the FAMHP into a “learning organisation”.

This release contains forward-looking information that involves substantial risks and uncertainties concerning the possibility of future dividend increases. Such risks and uncertainties include, among other things, the Company’s future financial performance as well as general economic, political, business, industry, regulatory and market conditions.
Such risks and uncertainties include, among other things, the Company’s future financial performance as well as general economic, political, business, industry, regulatory and market conditions.

Proactive contacts with the general and specialised press, various publications and information campaigns will be included together with future internal communication actions in a proper communication plan so as to implement a strategic communication policy as quickly as possible.
Proactive contacts with the general and specialised press, various publications and information campaigns will be included together with future internal communication actions in a proper communication plan so as to implement a strategic communication policy as quickly as possible.

The BUM department is legally required to provide support with putting online the list of medicines authorised in Belgium for new medicine MA and of the official information (Summary of Product Characteristics for healthcare professionals and leaflet for the general public).
The BUM department is legally required to provide support with putting online the list of medicines authorised in Belgium for new medicine MA and of the official information (Summary of Product Characteristics for healthcare professionals and leaflet for the general public).

This release contains forward-looking information about an agreement by Pfizer to acquire FoldRx, and about FoldRx’s product candidate tafamidis, its other clinical and preclinical development programs and its technology platform, including their potential benefits, that involves substantial risks and uncertainties. Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments. A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and in its reports on Form 10-Q and Form 8-K.
Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments.

information is being generated for the new
information is being generated for the new

Op 22/02/2008 werd de 'Guidance for Industry on Providing Regulatory Information in Electronic format: Non-eCTD electronic Submissions (NeeS)' gepubliceerd op de EMEA website: [http ...]
Le document 'Guidance for Industry on Providing Regulatory Information in Electronic format: Non-eCTD electronic Submissions (NeeS)' a été publié sur le site de l’EMEA le 22/02/2008 : [http ...]

Various roadshows were organised in order to inform the FAMHP stakeholders about this new activity within the FAMHP and to provide a coherent explanation of recent regulations regarding medicines for veterinary use and the distribution of these products in particular; the roadshows were organised for and in collaboration with the veterinarian professional organisations.
Various roadshows were organised in order to inform the FAMHP stakeholders about this new activity within the FAMHP and to provide a coherent explanation of recent regulations regarding medicines for veterinary use and the distribution of these products in particular; the roadshows were organised for and in collaboration with the veterinarian professional organisations.